Simrit Parmar

7.4k total citations · 1 hit paper
167 papers, 2.9k citations indexed

About

Simrit Parmar is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Simrit Parmar has authored 167 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hematology, 56 papers in Molecular Biology and 56 papers in Oncology. Recurrent topics in Simrit Parmar's work include Multiple Myeloma Research and Treatments (49 papers), Hematopoietic Stem Cell Transplantation (39 papers) and Acute Myeloid Leukemia Research (33 papers). Simrit Parmar is often cited by papers focused on Multiple Myeloma Research and Treatments (49 papers), Hematopoietic Stem Cell Transplantation (39 papers) and Acute Myeloid Leukemia Research (33 papers). Simrit Parmar collaborates with scholars based in United States, Canada and China. Simrit Parmar's co-authors include Leonidas C. Platanias, Martin S. Tallman, Nina Shah, Richard E. Champlin, Guillermo Garcia‐Manero, Uday Popat, Muzaffar H. Qazilbash, Antonella Sassano, Courtney DiNardo and Chitra Hosing and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Simrit Parmar

162 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

2013 539 citations Simrit Parmar, Guillermo Garcia‐Manero et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simrit Parmar United States	27	1.6k	1.3k	1.0k	963	466	167	2.9k
Hyeoung‐Joon Kim South Korea	29	1.4k 0.9×	1.0k 0.8×	909 0.9×	957 1.0×	524 1.1×	213	3.0k
Elizabeth O. Hexner United States	34	1.8k 1.1×	1.1k 0.9×	1.1k 1.1×	1.6k 1.7×	960 2.1×	154	4.0k
Maria Teresa Petrucci Italy	32	2.5k 1.6×	2.2k 1.7×	1.9k 1.8×	1.2k 1.2×	429 0.9×	156	4.1k
Ralph Wäsch Germany	31	2.1k 1.3×	1.6k 1.3×	1.2k 1.2×	389 0.4×	333 0.7×	172	3.3k
Yvonne A. Efebera United States	27	1.4k 0.9×	1.0k 0.8×	1.6k 1.5×	1.4k 1.4×	170 0.4×	150	3.0k
Stephan Mielke Germany	31	1.7k 1.1×	688 0.5×	1.9k 1.9×	1.6k 1.7×	257 0.6×	110	3.7k
Toshiko Motoji Japan	26	1.5k 1.0×	915 0.7×	578 0.6×	399 0.4×	700 1.5×	121	2.6k
George E. Georges United States	29	1.7k 1.1×	597 0.5×	585 0.6×	777 0.8×	641 1.4×	106	3.1k
Lydia Campos France	29	1.7k 1.1×	1.7k 1.3×	912 0.9×	479 0.5×	515 1.1×	106	3.3k
Camille L. Bedrosian United States	23	867 0.6×	732 0.6×	391 0.4×	1.4k 1.4×	456 1.0×	77	2.8k

Countries citing papers authored by Simrit Parmar

Since Specialization

Citations

This map shows the geographic impact of Simrit Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simrit Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simrit Parmar more than expected).

Fields of papers citing papers by Simrit Parmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simrit Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simrit Parmar. The network helps show where Simrit Parmar may publish in the future.

Co-authorship network of co-authors of Simrit Parmar

This figure shows the co-authorship network connecting the top 25 collaborators of Simrit Parmar. A scholar is included among the top collaborators of Simrit Parmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simrit Parmar. Simrit Parmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Ximing, et al.. (2025). Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE. Frontiers in Immunology. 16. 1449693–1449693. 1 indexed citations

Telli, Melinda L., Wei Mo, Amita Patnaik, et al.. (2024). 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 9. 103285–103285. 3 indexed citations

Masárová, Lucia, Meixian Huang, Swati Goel, et al.. (2024). A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.. Journal of Clinical Oncology. 42(16_suppl). 6580–6580. 1 indexed citations

Huang, Meixian, et al.. (2024). CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation. iScience. 27(9). 110830–110830. 6 indexed citations

Zeng, Ke, et al.. (2024). Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes. SHILAP Revista de lepidopterología. 3. 1448650–1448650. 1 indexed citations

Shneider, Neil A., Mengyuan Lyu, Wassim Elyaman, et al.. (2023). Immunotherapy: ADOPTIVE THERAPY WITH OFF THE SHELF, ALLOGENEIC, UMBILICAL CORD BLOOD, REGULATORY T CELLS SHOW SAFETY IN AMYOTROPHIC LATERAL SCLEROSIS. Cytotherapy. 25(6). S33–S34. 1 indexed citations

Gladstone, Douglas E., Franco R. D’Alessio, Christopher Howard, et al.. (2023). Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS. Blood Advances. 7(13). 3075–3079. 22 indexed citations

Lin, Paul, Rima M. Saliba, Uday Popat, et al.. (2019). Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation. 25(5). 1039–1044. 10 indexed citations

Ma, Hongbing, Uday Popat, Yago Nieto, et al.. (2019). Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial. Blood. 134(Supplement_1). 4547–4547. 1 indexed citations

10.

Kongtim, Piyanuch, Simrit Parmar, Denái R. Milton, et al.. (2018). Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation. 54(6). 839–848. 21 indexed citations

11.

Shah, Mithun Vinod, Rima M. Saliba, Gabriela Rondón, et al.. (2018). Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplantation. 54(4). 601–606. 25 indexed citations

12.

Mehta, Rohtesh S., Rima M. Saliba, Kai Cao, et al.. (2017). Ex Vivo Mesenchymal Precursor Cell–Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation. 23(8). 1359–1366. 23 indexed citations

13.

Steele, Joseph R., et al.. (2017). Use of an Online Education Platform to Enhance Patients’ Knowledge About Radiation in Diagnostic Imaging. Journal of the American College of Radiology. 14(3). 386–392. 14 indexed citations

14.

Thompson, Philip A., Katy Rezvani, Chitra Hosing, et al.. (2015). Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplantation. 50(S2). S55–S62. 16 indexed citations

15.

Parmar, Simrit & David Ritchie. (2014). Allogeneic transplantation as anticancer immunotherapy. Current Opinion in Immunology. 27. 38–45. 19 indexed citations

16.

Parmar, Simrit, Ryan Bookout, J. Shapiro, et al.. (2014). Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplantation. 49(6). 761–766. 15 indexed citations

17.

Parmar, Simrit, Xiaoying Liu, Simon N. Robinson, et al.. (2013). Third-party umbilical cord blood–derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 16(1). 90–100. 45 indexed citations

18.

Parmar, Simrit & Leonidas C. Platanias. (2005). Interferons. Cancer treatment and research. 126. 45–68. 9 indexed citations

19.

Kambhampati, Suman, Amit Kumar Verma, Yongzhong Li, et al.. (2004). Signalling Pathways Activated by All- trans -Retinoic Acid in Acute Promyelocytic Leukemia Cells. Leukemia & lymphoma. 45(11). 2175–2185. 24 indexed citations

20.

Parmar, Simrit, et al.. (2004). Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leukemia Research. 28(9). 909–919. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact